Vanderbilt TB Center News | Vanderbilt Tuberculosis Center

TBTC Launches CRUSH-TB trial

January 29, 2024

CDC’s Tuberculosis Trials Consortium (TBTC) has recently launched the CRUSH-TB trial, which aims to identify new combinations of drugs to shorten treatment of active TB disease. Kelly Dooley, MD, PhD, MPH, Director, Division of Infectious Diseases, is a Protocol Chair for this new study. Read more from CDC’s TB Notes newsletter:

CDC, TB Trials Consortium, Clinical Trial

Publication Announcement: “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis"

May 10, 2021

The U.S. Centers for Disease Control and Prevention (CDC) Tuberculosis Trials Consortium (TBTC), together with collaborators from the National Institutes of Health’s (NIH) AIDS Clinical Trial Group (ACTG), is pleased to announce the publication of “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis" in the New England Journal of Medicine.

TB, CDC, NIH

RSS: